MB-105 in Patients With CD5 Positive T-cell Lymphoma

This is a single arm, two-stage, Phase 2, open-label, multicenter study of MB-105 in patients with CD5 Positive (CD5+) Relapsed / Refractory T-cell Lymphoma (r/r TCL). This study will apply a Simon two-stage optimal design.

Trial Details

NCT ID
NCT06534060
Phase
PHASE2
Sponsor
March Biosciences Inc
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Genetic: MB-105
Locations (sample)
  • San Diego, California, United States|32.71571,-117.16472
  • Denver, Colorado, United States|39.73915,-104.9847
  • Tampa, Florida, United States|27.94752,-82.45843
  • Iowa City, Iowa, United States|41.66113,-91.53017
  • Boston, Massachusetts, United States|42.35843,-71.05977

Key Eligibility Criteria

  • Male or female ≥ 18 years of age.
  • Patients with r/r TCL per WHO 2022 criteria.
  • r/r CTCL that has failed ≥ 2 prior lines of standard of care (SoC) therapy.
  • r/r PTCL that has failed ≥ 1 prior lines of SoC therapy. Note: patients with CD30+ disease should have received brentuximab vedotin.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →